Vista AI, Inc. appears in FDA 510(k) records as the applicant for imaging software regulated as a Class II magnetic resonance diagnostic device under product code LNH and regulation number 892.1000. The company’s own published pages describe a first product, Vista AI Scan, that automates and simplifies image acquisition, with an initial focus on cardiac MRI and stated plans to extend to the brain, prostate, spine and other anatomical areas. The record set reviewed here covers two clearances: K251029, decided August 21, 2025, and K260092, decided October 7, 2026. [1][4][8]
Documented clearances and filing scope
K260092 covers a device named Vista AI Scan, received January 12, 2026 and decided October 7, 2026 as substantially equivalent under a Traditional review not handled by a third party. The FDA record lists the advisory committee as Radiology, the submission as containing a Summary, and a Predetermined Change Control Plan as authorized. The earlier K251029 clearance letter, dated August 21, 2025, names Vista OS, Vista AI Scan and RTHawk together under the same regulation and product code, describing the software as an accessory to 1.5T and 3.0T whole-body magnetic resonance diagnostic devices. [1][2][4]
The supplied collection holds one linked 510(k) record, and its decision count shows that single record as substantially equivalent; the smaller record sample likewise contains one entry, K260092. These figures describe the retrieved filings as of the snapshot date and are not measures of total portfolio, sales or safety performance. [1]
What the software is described to do
Vista AI’s product pages state that Vista AI Scan automates cardiac MRI scanning so that existing staff can deliver consistent imaging across sites of service, a task the company says previously required a specialist at a flagship site. The same pages state that technologists can still make adjustments, and that the company’s clinical team works with customers to load a standardized protocol set, which can draw on sequences from the customer’s existing scanner or on the company’s stated 30+ FDA-cleared sequences. [3][6]
The company’s homepage frames the effort around access, citing rising demand, staffing shortages and clinical complexity as pressures on imaging programs, and describes automation of gold-standard MRI beginning with cardiac imaging. The About page names Bob Hu as Chief Medical Officer and co-founder and Juan Santos as Chief Executive Officer. [5][8]
Identity, locations and limits of the record
FDA filings give a Palo Alto, California address for the applicant, and the K251029 letter carries the same street address; the company’s published pages list a Redwood City, California address. A filing address is a regulatory contact location and does not establish a headquarters. No parent company, brand owner or corporate ownership structure is verified in these records. [1][4][5]
The reviewed material does not document customers, installed sites, independent clinical performance results, commercial availability dates or certifications beyond the clearances described. Claims about consistency, speed and image quality originate with the manufacturer’s published documentation rather than from the FDA records, which address clearance status and indicated device scope. [2][3][4]
